Subcutaneous Biodegradable Polymer for Nail Matrix Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for onychomycosis and nail diseases are limited by poor accessibility, low effectiveness, frequent administration, and prolonged treatment durations, leading to non-compliance and recurrence of infections due to high doses of antifungals with systemic side effects, and the inability to target the nail matrix effectively.
Innovation Solution
A biodegradable solid polymer composition with sustained release, administered subcutaneously at a distance from the nail, optionally containing antifungal agents, to provide prolonged treatment with reduced doses and improved accessibility to the nail matrix, avoiding invasive procedures and minimizing systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of antifungals are administered systemically, then the treatment effectiveness is improved, but the side effects and toxicity increase
Solution Approach 1:
The patent applies local quality by delivering antifungal agents directly to the nail matrix through subcutaneous injection in the proximal nail fold, creating a localized high-concentration environment at the infection source while minimizing systemic absorption. This allows effective treatment with reduced overall antifungal dosage.
Solution Approach 2:
The patent uses the proximal nail fold tissue as an intermediary delivery system. The subcutaneous injection site acts as a mediator that releases antifungals locally into the nail matrix through diffusion and lymphatic drainage, serving as a bridge between the injection site and the infected area without requiring direct intranail injection.
2Manufacturing precision
If invasive procedures are used to target the nail matrix directly, then the accessibility to the infection source is improved, but the patient comfort and compliance deteriorate
Solution Approach 1:
The patent uses the proximal nail fold as an intermediary access point. Instead of directly injecting into the nail matrix (which would be invasive and painful), the subcutaneous injection site serves as a mediator that delivers antifungals to the matrix through tissue diffusion and lymphatic pathways, making the procedure less invasive and more compliant.
Solution Approach 2:
The patent replaces direct mechanical injection into the nail matrix with a subcutaneous injection system that uses biological transport mechanisms (diffusion and lymphatic drainage) to deliver the antifungals. This substitution eliminates the need for direct intranail puncture, reducing pain and improving compliance.
3Reliability
If frequent administrations are required, then the treatment coverage is improved, but the loss of time and patient burden increase
Solution Approach 1:
The patent applies preliminary action by administering antifungals in advance through subcutaneous injection into the proximal nail fold, which then releases the medication over an extended period. This preliminary delivery establishes therapeutic levels before the injection, allowing for less frequent administrations while maintaining continuous treatment coverage.
Solution Approach 2:
The patent ensures continuity of useful action through the sustained-release mechanism of subcutaneous injection. The antifungal agents are released gradually over weeks or months, maintaining continuous therapeutic levels in the nail matrix without requiring frequent re-administration, thus eliminating treatment gaps while reducing patient burden.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition allows for effective treatment of onychomycosis and nail diseases with reduced antifungal doses, prolonged action, and enhanced accessibility to the nail matrix, reducing recurrence and side effects, while maintaining compliance through less frequent administrations.
Implementation Method 1
A biodegradable solid polymer composition with sustained release, administered subcutaneously at a distance from the nail
Implementation Method 2
one or more solid biodegradable polymers with prolonged release
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to injectable prolonged-action compositions for use in the treatment of nail diseases, including potentially promoting the growth of the nail, or for use promoting the growth of the nail.